In recent years, the incredible boost in stem cell research has kindled the expectations of both patients and physicians.\r\nMesenchymal progenitors, owing to their availability, ease of manipulation, and therapeutic potential, have become one of the\r\nmost attractive options for the treatment of a wide range of diseases, from cartilage defects to cardiac disorders. Moreover, their\r\nimmunomodulatory capacity has opened up their allogenic use, consequently broadening the possibilities for their application. In\r\nthis review, we will focus on their use in the therapy of myocardial infarction, looking at their characteristics, in vitro and in vivo\r\nmechanisms of action, as well as clinical trials.
Loading....